S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
FMC stock just set a new ceiling higher, 50% higher indeed
Biden Out, _______ In? (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
FMC stock just set a new ceiling higher, 50% higher indeed
Biden Out, _______ In? (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
FMC stock just set a new ceiling higher, 50% higher indeed
Biden Out, _______ In? (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
S&P 500   5,026.61
DOW   38,671.69
QQQ   437.05
Israel's finance minister blasts Moody's downgrade of the the country's credit rating
Obama’s 2024 Confession (Ad)
Mardi Gras beads are creating a plastic disaster in New Orleans. Are there green alternatives?
Super Bowl Live Updates | 49ers are Super Bowl favorites in 2025
Biden Out, _______ In? (Ad)
Recession risks are fading, business economists say, but political tensions pose threat to economy
FMC stock just set a new ceiling higher, 50% higher indeed
Biden Out, _______ In? (Ad)
Venezuela defends military buildup, accusing neighboring Guyana of granting illegal oil contracts
Stock market today: World shares mostly higher after S&P 500 tops 5,000
NASDAQ:JSPR

Jasper Therapeutics (JSPR) Stock Price, News & Analysis

$17.59
+0.23 (+1.32%)
(As of 02/9/2024 08:56 PM ET)
Today's Range
$16.23
$17.90
50-Day Range
$4.24
$17.59
52-Week Range
$4.00
$21.90
Volume
82,100 shs
Average Volume
137,285 shs
Market Capitalization
$196.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.63

Jasper Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
239.0% Upside
$59.63 Price Target
Short Interest
Healthy
2.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Jasper Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$4.54 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($6.16) to ($6.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

408th out of 922 stocks

Biotechnology Industry

7th out of 24 stocks


JSPR stock logo

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

JSPR Stock Price History

JSPR Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
New Trump Bombshell
I believe Donald J. Trump will go down as America’s last Republican president.  But NOT for the reasons you may think…  If I’m right, the soul of this country will change forever…
JSPR Feb 2024 10.000 call
Jasper Therapeutics, Inc. Announces Reverse Stock Split
Jasper Therapeutics: Q3 Earnings Insights
Jasper Therapeutics Inc.
See More Headlines
Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/12/2024
Next Earnings (Estimated)
3/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:JSPR
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.63
High Stock Price Target
$70.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+239.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-37,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.46 per share

Miscellaneous

Free Float
10,723,000
Market Cap
$196.30 million
Optionable
Optionable
Beta
1.98
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Ronald A. Martell (Age 62)
    President, CEO & Director
    Comp: $892.45k
  • Dr. Judith Anne Shizuru M.D. (Age 68)
    Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
    Comp: $291.25k
  • Mr. Jeetinder Singh Mahal M.B.A. (Age 52)
    Chief Operating Officer
    Comp: $579.46k
  • Mr. Herbert C. Cross (Age 52)
    CFO & Corporate Secretary
  • Dr. Luca Di Noto Ph.D.
    Senior Vice President of Technical Operations
  • Mr. David Ku M.D.
    Vice President of Corporate Development, Portfolio Strategy & Management
  • Mr. Matthew Ford
    Vice President of Human Resources
  • Dr. Wendy Pang M.D.
    Ph.D., Senior Vice President of Research & Translational Medicine
  • Dr. Edwin Jonathan Tucker M.D. (Age 52)
    Chief Medical Officer
  • Ms. Patricia Carlos
    Senior Vice President of Regulatory Affairs & Quality














JSPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings
or view top-rated stocks.

What is Jasper Therapeutics' stock price target for 2024?

5 brokerages have issued 12-month price objectives for Jasper Therapeutics' shares. Their JSPR share price targets range from $40.00 to $70.00. On average, they predict the company's stock price to reach $59.63 in the next twelve months. This suggests a possible upside of 239.0% from the stock's current price.
View analysts price targets for JSPR
or view top-rated stocks among Wall Street analysts.

How have JSPR shares performed in 2024?

Jasper Therapeutics' stock was trading at $7.89 at the beginning of the year. Since then, JSPR shares have increased by 122.9% and is now trading at $17.59.
View the best growth stocks for 2024 here
.

When is Jasper Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our JSPR earnings forecast
.

When did Jasper Therapeutics' stock split?

Shares of Jasper Therapeutics reverse split on the morning of Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Fernwood Investment Management LLC (4.43%), Monaco Asset Management SAM (2.24%), Ieq Capital LLC (0.49%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans, Velan Capital Investment Manag and William Lis.
View institutional ownership trends
.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JSPR) was last updated on 2/12/2024 by MarketBeat.com Staff

My Account -